Company intelligence / Profile preview

LightEyez

London, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

No clinical results published; company cites internal surveys and testimonial data only. FDA found gross microbial contamination in recent product tests and has issued warnings to consumers to avoid the products, which are also considered adulterated and illegal to market as drugs in the US.

Therapeutic areas: Ophthalmology
Modalities: Non-pharmacological therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on LightEyez.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LightEyez.

Explore the full profile